AUTHORS
Fengkui Zhang, MD, Bing Han, MD2, Hongyan Tong, MD, PhD3, Li Zhang4, Chen Yang5, Gaixiang Xu6, Shun-Qing Wang7, Rongrong Liu, PhD8, Qin Wen9, Fei Li, MD, PhD10, Ling Nie, PhD11, Xiequn Chen12, Hu Zhou, MD13, Jinhai Ren, MD14, Liping Jing, MD15, Yumeng Zhou, PhD16, Rongfeng Zhou17
AFFILIATIONS
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, tianjin, China
2 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, beijing, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, hangzhou, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, tianjin, tianjin, China
5 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, beijing, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, hangzhou, China
7 Guangzhou First People's Hospital, guangzhou, China
8 The First Affiliated Hospital of Guangxi Medical University, nanning, China
9 The Second Affiliated Hospital of Army Medical University, chongqing, China
10 The First Affiliated Hospital of Nanchang University, nanchang, China
11 Xiangya Hospital, Central South University, changsha, China
12 Xi'an No.3 Hospital, xian, China
13 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, zhengzhou, China
14 The Second Hospital of Hebei Medical University, shijiazhuang, China
15 Beijing Boren Hospital (Gaobo Medical Group), beijing, China
16 Nanjing Chia Tai-Tianqing Pharmaceutical Co., Ltd., nanjing, China
17 Nanjing Chia Tai-Tianqing Pharmaceutical Co., Ltd., nanjing, China
ABSTRACT
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by complement-mediated hemolysis. Although C5 inhibitors improve outcomes, residual anemia may persist due to incomplete control of C3-mediated extravascular hemolysis. NTQ5082 is a novel oral selective complement factor B (CFB) inhibitor with a long half-life enabling once-daily dosing.
Methods: This multicenter, randomized, open-label, active-controlled phase 3 study conducted in China enrolled adults with PNH who were complement inhibitor-naïve and had active hemolysis (NCT07177859). Patients were randomized 2:1, stratified by central laboratory baseline hemoglobin (Hb; ≤70 or >70 g/L), to NTQ5082 200 mg once daily or eculizumab for 24 weeks. The primary efficacy endpoint was the proportion of patients with hemoglobin (Hb) ≥120 g/L at least 3 of 4 assessments from Week 18 to Week 24 and no red blood cell (RBC) transfusion from Week 2 to Week 24. Secondary endpoints included the proportions of patients achieving an Hb increase of ≥20 g/L, transfusion avoidance, and hemolysis control (LDH ≤1.5×ULN), changes in Hb, reticulocyte count, C3 fragment deposition, and Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue) score, as well as safety.
Results: Eighty patients were included in the analysis (NTQ5082, n=55; eculizumab, n=25). Baseline characteristics were generally comparable. Mean ages were 39.3 and 38.6 years, and 47.3% and 52.0% of patients were female, in the NTQ5082 and eculizumab groups, respectively. Mean Hb levels were 72.2 and 67.1 g/L, and mean LDH was 1893.6 and 1692.2 U/L in the NTQ5082 and eculizumab groups, respectively.
NTQ5082 treatment provided clinically meaningful Hb improvement. At Week 24, mean Hb levels were 136.0 and 96.0 g/L, with least-squares mean changes from baseline of 63.8 and 28.4 g/L in the NTQ5082 and eculizumab groups, respectively. The primary endpoint was achieved in 87.3% (48/55; 95% CI: 75.5%-94.7%) and 4.0% (1/25; 95% CI: 0.1%-20.4%) of patients, respectively (OR, 164.57; 95% CI: 19.13-1415.45; P<0.0001). All NTQ5082-treated patients remained transfusion-free after Day 15, while one patient in the eculizumab group received RBC transfusion thereafter.
At Week 24, the proportions of patients achieving an Hb increase from baseline of ≥20 g/L were 98.1% (53/54; 95% CI: 90.1%-100.0%) in the NTQ5082 group and 60.0% (15/25; 95% CI: 38.7%-78.9%) in the eculizumab group.
NTQ5082 treatment showed consistent improvement in hemolysis-related parameters. At Week 2, LDH decreased by 85.3% from baseline in the NTQ5082 group, and the proportion of patients with LDH ≤1.5×ULN was 96.4% (53/55; 95% CI: 87.5%-99.6%). At Week 24, LDH decreased by 83.7% and 82.3% from baseline in the NTQ5082 and eculizumab groups, respectively. Mean C3 fragment deposition decreased from 0.377% to 0.076% in the NTQ5082 group but increased from 0.264% to 7.223% in the eculizumab group. Mean reticulocyte count decreased from 0.257×10¹²/L to 0.128×10¹²/L with NTQ5082 and changed from 0.241×10¹²/L to 0.268×10¹²/L with eculizumab. Mean FACIT-Fatigue score changes from baseline were +8.3 and +5.1 points, respectively. NTQ5082 was superior to eculizumab in magnitude of Hb improvement, reduction in reticulocyte count, and improvement in FACIT-Fatigue score, while reducing C3 fragment deposition compared with eculizumab..
NTQ5082 was generally well tolerated. Through Week 24, Treatment-emergent adverse events (TEAEs) occurred in 89.1% and 72.0% of patients receiving NTQ5082 and eculizumab, respectively, and were predominantly Grade 1 or 2. The most common TEAEs in the NTQ5082 group included upper respiratory tract infection (32.7%), headache (21.8%), and dyslipidemia (23.6%). Breakthrough hemolysis events were associated with infection, non-adherence to dosing regimen, or other external triggers and were not considered drug-related. No deaths were reported.
Conclusions: NTQ5082 200 mg once daily in complement inhibitor-naïve patients with PNH provided rapid and sustained hemolysis control and transfusion-free improvement in Hb levels. Compared with eculizumab, NTQ5082 demonstrated superior efficacy in achieving Hb normalization without RBC transfusion. With its once-daily dosing regimen, substantial Hb improvement, and favorable safety profile, NTQ5082 has the potential to be a competitive CFB inhibitor in the treatment of PNH.
DISCLOSURES
Fengkui Zhang, MD: No relevant conflicts of interest to declare.